Ad
related to: ventricular fibrillation merck medicationwexnermedical.osu.edu has been visited by 10K+ users in the past month
262 Neil Avenue # 430, Columbus, Ohio · Directions · (614) 221-7464- Should I See a Heart Doc
Talk to your doc about your heart
and learn what to ask
- Prepare For Your Visit
What to bring to your visit
plus heart & vascular resources
- Patient Testimonials
Hear from our patients
about their Ohio State experience
- Find a Doctor
Meet with our experts to diagnose
your symptoms and receive treatment
- Should I See a Heart Doc
Search results
Results from the WOW.Com Content Network
The dose is 5–10 mg/kg and side effects are high blood pressure followed by low blood pressure and ventricular ectopy. Originally introduced in 1959 for the treatment of hypertension. [2] Its use as an antiarrhythmic for ventricular fibrillation was discovered and patented by Marvin Bacaner in 1969 at the University of Minnesota. [3]
Ventricular fibrillation (V-fib or VF) is an abnormal heart rhythm in which the ventricles of the heart quiver. [2] It is due to disorganized electrical activity. [2] Ventricular fibrillation results in cardiac arrest with loss of consciousness and no pulse. [1] This is followed by sudden cardiac death in the absence of treatment. [2]
Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a class of drugs that are used to suppress abnormally fast rhythms (tachycardias), such as atrial fibrillation, supraventricular tachycardia and ventricular tachycardia.
Vernakalant was initially developed by Cardiome Pharma, and the intravenous formulation was bought for further development by Merck in April 2009. [5] In September 2012, Merck terminated its agreements with Cardiome and has consequently returned all rights of the drug back to Cardiome, which as of 2018 is known as Correvio Pharma. [citation needed]
The drug is additionally available ... (particularly halothane), tachyarrhythmias or ventricular fibrillation, ... when Merck began marketing and selling the drug as ...
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary ...
Flecainide is a medication used to prevent and treat abnormally fast heart rates. [1] This includes ventricular and supraventricular tachycardias. [1] Its use is only recommended in those with dangerous arrhythmias or when significant symptoms cannot be managed with other treatments. [1] Its use does not decrease a person's risk of death. [1]
The term ventricular arrhythmia refers to the group of abnormal cardiac rhythms originating from the ventricle, which includes ventricular tachycardia, ventricular fibrillation, and torsades de pointes. [2] In those who have normal blood pressure and strong pulse, the antiarrhythmic medication procainamide may be used. [2]
Ad
related to: ventricular fibrillation merck medicationwexnermedical.osu.edu has been visited by 10K+ users in the past month
262 Neil Avenue # 430, Columbus, Ohio · Directions · (614) 221-7464